BGPT: Author Review: Kamil Bojarczuk

Fuel Your Discoveries

Quick Explanation Copied

Kamil Bojarczuk — evidence-grounded scientific snapshot

Bibliometric indicators from OpenAlex: ~1,276 cited_by and h-index ~16 across ~45 works (OpenAlex record).

Core research themes visible in the record align with cancer biology / immunology, including B-cell malignancies and immune evasion mechanisms.

Evidence limitations: this review is constrained to the provided bibliometric metadata and the OpenAlex-indexed DOIs/titles explicitly present in your input.

Key metrics (OpenAlex):

Works: ~45, cited_by: ~1,276, h-index: ~16 — OpenAlex author page.

Long Explanation

Author Review — Kamil Bojarczuk (evidence-grounded, skeptical)

Scope: This review is limited to (i) the OpenAlex bibliometric metadata you provided and (ii) the specific OpenAlex-indexed works where a DOI was explicitly present in your input. It does not attempt to infer experimental findings beyond what your provided record allows.

1) Bibliometric indicators (from OpenAlex)

These are community attention proxies, not direct measures of experimental rigor. Publication and citation practices vary by field, time, and journal.

OpenAlex record indicates ~45 works, ~1,276 cited_by, and h-index ~16 for Kamil Bojarczuk.
OpenAlex also provides OA flags for some top works in the same record; this review does not interpret OA as quality.

2) Thematic focus suggested by the provided work titles/DOIs

From the titles present in your input (and the OpenAlex topics provided), the author’s visible footprint concentrates on cancer biology, including lymphoid malignancies (e.g., DLBCL/CLL/Burkitt, Hodgkin lymphoma) and mechanistic links to immune interactions/evasion and therapeutic target modulation (e.g., CD20 expression).

Important epistemic humility: a citation-rich profile does not establish correctness of any single claim, and high citation counts can reflect many factors.

3) Example OpenAlex-indexed works (explicit DOIs in your input)

Below is an evidence-grounded “anchor set” of works where a DOI was explicitly provided in your OpenAlex excerpt. This is not a complete list of the author’s papers.

Year	Title	Journal (from OpenAlex)	DOI	Cited-by (OpenAlex snapshot)	Open Access (OpenAlex)
2011	Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer	Molecules	10.3390/molecules16054140	259	Gold (OpenAlex record shows OA status for this top work)
2019	Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion	Blood Advances	10.1182/bloodadvances.2019001012	161	Gold
2020	EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity	Blood	10.1182/blood.2020008520	116	Bronze
2016	BCR signaling inhibitors differ in their ability to overcome Mcl-1–mediated resistance of CLL B cells to ABT-199	Blood	10.1182/blood-2015-10-675009	113	Bronze
2018	Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL	Blood	10.1182/blood-2018-08-872465	95	Bronze
2017	HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies	Blood	10.1182/blood-2016-08-736066	51	Bronze

Evidence notes: the table’s cited-by counts and OA status fields come from the provided OpenAlex excerpt.

4) Mechanistic interpretation strength (what we can and cannot infer)

What the included metadata supports

Immuno-oncology and lymphoid malignancies appear repeatedly in the OpenAlex-derived anchor set (e.g., immune evasion in Hodgkin Reed–Sternberg cells; EBV-associated PCNSL after immunosuppression; CLL resistance to ABT-199; DLBCL subtypes with PI3Kα/δ and BCL-2 blockade).
Therapeutic-target modulation is suggested by titles related to CD20 regulation and synergy/resistance within B-cell signaling contexts.

What we cannot conclude from this input alone

We cannot verify experimental design details (controls, blinding, sample sizes, replication, effect sizes) solely from titles and bibliometric metadata. Those require full-text extraction.
We cannot distinguish whether claims have been replicated or contradicted in later work without accessing subsequent literature and the methods/results sections of each cited paper.
There is a risk of citation/attention bias: highly cited papers can include both high-impact discoveries and influential but imperfect findings.

5) Evidence-based “strength signals” you can check next

If you want to evaluate scientific strength beyond bibliometrics, focus on:

Methodological rigor: independent biological replicates; quantification; orthogonal assays; statistical methods; and whether key mechanistic links are causally supported.
Reproducibility: whether the same pathway perturbations yield consistent results across model systems.
External validity: whether findings generalize across patient-derived samples or only one cohort.
Interpretation discipline: whether the paper avoids over-attribution (correlation vs causation) and provides mechanistic convergence.

6) Optional deep-dive anchors (direct paper links)

These are the DOI-linked anchor points from your input; clicking them will help you verify methods/results in the full text.

Confidence & disconfirming data

High confidence in the bibliometric statements because they directly derive from the OpenAlex record you provided.
Lower confidence in any implied mechanistic strength of the author’s conclusions because we have not extracted full-text methods/results for replication/robustness checks.
Would change my view if full-text extraction reveals non-reproducibility, weak sample sizes, insufficient causal tests, or results that contradict later replication cohorts.

Feedback:

Updated: April 25, 2026